PAOG CBD Nutraceuticals Rollout On Track Targeting $5 Billon Market
June 17 2021 - 12:02PM
InvestorsHub NewsWire
Sandusky, OH
-- June 17, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc.
(USOTC:
PAOG) today confirmed the company’s plan to launch a CBD
Nutraceuticals line of products expected to generate revenue this
year, in 2021, is on track. The company also continues in the
long-term CBD
pharmaceutical.
Next week, on
Wednesday, June 23rd, management will release an update
on the company’s CBD Nutraceuticals development initiative to
include new developments expected to expand PAOG’s overall market
opportunity.
The 2020 CBD
Nutraceuticals Market had an estimated
value of $5.2 Billion and it is expected to reach $16.4 Billion by
2027.
PAOG is working
on the development of a CBD pharmaceutical product under the name
RespRx, for the treatment of Chronic
Obstructive Pulmonary Disorder (COPD) derived from a patented
cannabis extraction method - U.S. Patent No. 9,199,960 entitled
"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS
PLANT."
PAOG plans to
develop and distribute its CBD nutraceuticals with Alkame Holdings,
Inc. (OTC
Pink: ALKM) as a copacker and North American Cannabis Holdings,
Inc. (OTC
Pink: USMJ) as a
distributor.
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Sep 2024 to Oct 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Oct 2023 to Oct 2024